Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

NCT00262288 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT00262288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00262288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2/3
Overall status
Completed
Start date
April 30, 2004
Completion date
January 31, 2007
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic disorders